Gantenerumab data presented at CTAD- ADDF statement - Video

The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer's will require drugs that do more than clear amyloid plaques. While lecanemab had an effect on slowing cognitive decline and removing amyloid plaques in the brain, gantenerumab had neither effect.

This was a historic Clinical Trial on Alzheimer's Disease conference, reflecting tremendous progress in Alzheimer's research and drug development. There have been a lot of encouraging news, including the lecanemab results and clinical trial data from other classes of drugs that demonstrate the diversity of the pipeline. The mixed data shows that while anti-amyloids are a promising starting point, however, there will be need for a combination of drugs aimed at different targets.

The rapidly advancing drug pipeline is matched by ongoing breakthroughs in accessible and affordable diagnostic tools that can tell which underlying causes are at play in each person's Alzheimer's condition. Researchers are also making advances in the use of digital tools, including wearable devices and at home digital tests, to provide earlier-than-ever diagnosis of Alzheimer's, perhaps even before symptoms are evident.

Reference:

ADDF statement on gantenerumab data presented at CTAD; ALZHEIMER'S DRUG DISCOVERY FOUNDATION